EAM
STSA

Eventide Asset Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Eventide Asset Management’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-983,382
Closed -$28.3M – 153
2020
Q2 		$28.3M Hold
983,382
– – 0.61% 58
2020
Q1 		$20.6M Buy
983,382
+558,382
+131% +$12.7M 0.67% 59
2019
Q4 		$8.36M Hold
425,000
– – 0.24% 82
2019
Q3 		$6.38M Buy
+425,000
New +$6.59M 0.21% 83

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Eventide Asset Management's STSA Position: Q3 2020 in Review

Eventide Asset Management sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2020, closing a stake of 983,382 shares — an estimated $28.3M sold.

Eventide Asset Management first reported a position in STSA in Q3 2019 and held it in 4 quarters. The position peaked at $28.3M in Q2 2020. 46 funds tracked by Wall St. Rank hold STSA as of Q3 2020.

  • Eventide Asset Management reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Eventide Asset Management sold 983,382 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $28.3M.
  • Eventide Asset Management first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
  • Eventide Asset Management's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $28.3M in Q2 2020.
  • 46 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Eventide Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.